- Home
- MULN vs SLXN Comparison
MULN vs SLXN Comparison
Compare MULN & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MULN
- SLXN
- Stock Information
- Founded
- MULN 2014
- SLXN 2008
- Country
- MULN United States
- SLXN Israel
- Employees
- MULN N/A
- SLXN N/A
- Industry
- MULN Auto Manufacturing
- SLXN
- Sector
- MULN Consumer Discretionary
- SLXN
- Exchange
- MULN Nasdaq
- SLXN NYSE
- Market Cap
- MULN 6.5M
- SLXN 7.3M
- IPO Year
- MULN N/A
- SLXN N/A
- Fundamental
- Price
- MULN $0.62
- SLXN $0.81
- Analyst Decision
- MULN
- SLXN Strong Buy
- Analyst Count
- MULN 0
- SLXN 1
- Target Price
- MULN N/A
- SLXN $5.00
- AVG Volume (30 Days)
- MULN 8.0M
- SLXN 236.5K
- Earning Date
- MULN 08-11-2025
- SLXN 08-21-2025
- Dividend Yield
- MULN N/A
- SLXN N/A
- EPS Growth
- MULN N/A
- SLXN N/A
- EPS
- MULN N/A
- SLXN N/A
- Revenue
- MULN $8,931,612.00
- SLXN N/A
- Revenue This Year
- MULN N/A
- SLXN N/A
- Revenue Next Year
- MULN N/A
- SLXN N/A
- P/E Ratio
- MULN N/A
- SLXN N/A
- Revenue Growth
- MULN 2136.62
- SLXN N/A
- 52 Week Low
- MULN $0.59
- SLXN $0.58
- 52 Week High
- MULN $154,200,000.00
- SLXN $41.85
- Technical
- Relative Strength Index (RSI)
- MULN 20.72
- SLXN N/A
- Support Level
- MULN $1.62
- SLXN N/A
- Resistance Level
- MULN $1.64
- SLXN N/A
- Average True Range (ATR)
- MULN 0.91
- SLXN 0.00
- MACD
- MULN 152.97
- SLXN 0.00
- Stochastic Oscillator
- MULN 0.66
- SLXN 0.00
About MULN Mullen Automotive Inc.
Mullen Automotive Inc is engaged in manufacturing electric vehicles and building energy solutions. Its portfolio of vehicles is predominantly comprised of commercial trucks and other electric vehicles and includes; Mullen Class 1 Cargo Van, Mullen Three, Bollinger B4 Chassis Cab, and Mullen I-GO. The company's operating segments are Bollinger which derives maximum revenue, and Mullen Commercial.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.